Witte Steven, Bradley Allan, Enright Anton J, Muljo Stefan A
Integrative Immunobiology Unit, Laboratory of Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, UK.
BMC Genomics. 2015 Nov 6;16:903. doi: 10.1186/s12864-015-1905-6.
Transcriptional enhancers are frequently bound by a set of transcription factors that collaborate to activate lineage-specific gene expression. Recently, it was appreciated that a subset of enhancers comprise extended clusters dubbed stretch- or super-enhancers (SEs). These SEs are located near key cell identity genes, and enriched for non-coding genetic variations associated with disease. Previously, SEs have been defined as having the highest density of Med1, Brd4 or H3K27ac by ChIP-seq. The histone acetyltransferase P300 has been used as a marker of enhancers, but little is known about its binding to SEs.
We establish that P300 marks a similar SE repertoire in embryonic stem cells as previously reported using Med1 and H3K27ac. We also exemplify a role for SEs in mouse T helper cell fate decision. Similarly, upon activation of macrophages by bacterial endotoxin, we found that many SE-associated genes encode inflammatory proteins that are strongly up-regulated. These SEs arise from small, low-density enhancers in unstimulated macrophages. We also identified expression quantitative trait loci (eQTL) in human monocytes that lie within such SEs. In macrophages and Th17 cells, inflammatory SEs can be perturbed either genetically or pharmacologically thus revealing new avenues to target inflammation.
Our findings support the notion that P300-marked SEs can help identify key nodes of transcriptional control during cell fate decisions. The SE landscape changes drastically during cell differentiation and cell activation. As these processes are crucial in immune responses, SEs may be useful in revealing novel targets for treating inflammatory diseases.
转录增强子经常与一组转录因子结合,这些转录因子协同作用以激活谱系特异性基因表达。最近,人们认识到一部分增强子组成了被称为拉伸或超级增强子(SEs)的扩展簇。这些SEs位于关键细胞身份基因附近,并富集了与疾病相关的非编码遗传变异。以前,SEs被定义为通过ChIP-seq具有最高密度的Med1、Brd4或H3K27ac。组蛋白乙酰转移酶P300已被用作增强子的标志物,但对其与SEs的结合了解甚少。
我们确定P300在胚胎干细胞中标记了与先前使用Med1和H3K27ac报道的类似的SEs库。我们还举例说明了SEs在小鼠辅助性T细胞命运决定中的作用。同样,在用细菌内毒素激活巨噬细胞后,我们发现许多与SEs相关的基因编码强烈上调的炎症蛋白。这些SEs来自未刺激巨噬细胞中的小的、低密度增强子。我们还在人类单核细胞中鉴定了位于此类SEs内的表达数量性状位点(eQTL)。在巨噬细胞和Th17细胞中,炎症SEs可以通过遗传或药理学方法受到干扰,从而揭示了针对炎症的新途径。
我们的研究结果支持这样一种观点,即P300标记的SEs有助于识别细胞命运决定过程中转录控制的关键节点。SEs景观在细胞分化和细胞激活过程中发生巨大变化。由于这些过程在免疫反应中至关重要,SEs可能有助于揭示治疗炎症性疾病的新靶点。